Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 2/20 | 0.74 |
| ▸ | IL15 | P40933 | 16/20 | 0.58 |
| ▸ | IL15RA | Q13261 | 15/20 | 0.58 |
| ▸ | IL2 | P60568 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15811545 | 0.84 | CNKSR1 (1.00) | CNKSR1IL15IL15RAIL2THRA | |
| SCHEMBL17293820 | 0.76 | IL15 (0.69) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL17293630 | 0.74 | IL15 (0.63) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL17293542 | 0.74 | IL15 (1.00) | IL15IL15RAIL2 | |
| SCHEMBL17293580 | 0.73 | IL15 (1.00) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL17293576 | 0.72 | IL15 (0.82) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL17293533 | 0.69 | IL15 (0.58) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL4203150 | 0.69 | ALDH1A1 (0.64) | NPC1RAB9A | |
| SCHEMBL17293579 | 0.69 | IL15 (0.76) | CNKSR1IL15IL15RAIL2 | |
| SCHEMBL17293615 | 0.69 | IL15 (1.00) | IL15IL15RAIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765797-B2 | TG2 inhibitors and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765797-B2 | TG2 inhibitors and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130158087-A1 | TG2 INHIBITORS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158087-A1 | TG2 INHIBITORS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158087-A1 | TG2 INHIBITORS AND USES THEREOF | TGM2, TGM3, GNMT | CNKSR1 4453/4885IL15 4542/4885IL15RA 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.